BAY 3563254
Alternative Names: 225Ac-PSMA-Trillium; Ac 225 conjugated small molecule - Bayer; Actinium-labeled PSMA-targeted alpha therapy - Bayer; BAY-3563254; PSMA SMOL TAC - BayerLatest Information Update: 11 Apr 2024
At a glance
- Originator Nora Therapeutics; SMA Therapeutics
- Developer Bayer
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 07 Mar 2024 Phase-I clinical trials in Prostate cancer (Late-stage disease, Hormone refractory, Second-line therapy or greater, Metastatic disease) in Canada (IV) (NCT06217822) (EudraCT2023-507486-26-00)
- 23 Jan 2024 Bayer plans a phase I PAnTHA trial for Prostate cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in Belgium, Canada and United Kingdom (NCT06217822)
- 28 Nov 2023 Phase-0 for Prostate cancer (Late-stage disease) (Parenteral) prior to November 2023(Parenteral) (Bayer pipeline, November 2023)